Advertisement

Drugs

, Volume 65, Issue 1, pp 99–107 | Cite as

Desmopressin

In Adults with Nocturia
Adis Drug Profile

Abstract

▴ Desmopressin, a synthetic antidiuretic hormone analogue, is the only drug currently approved for the treatment of nocturia associated with nocturnal polyuria or multiple sclerosis (MS). Compared with vasopressin, desmopressin has a longer lasting and more potent antidiuretic effect and is devoid of vasopressor and uterotonic effects.

▴ In two large, randomised, double-blind phase III trials in adults with nocturia associated with nocturnal polyuria, 3 weeks of oral desmopressin therapy was significantly more effective than placebo in reducing the mean number of nocturnal voids and in normalising the rate of nocturnal urine production.

▴ Beneficial effects of desmopressin on nocturia were maintained and increased in patients completing 10 or 12 months of further treatment in a nonblind extension of short-term trials.

▴ In randomised, double-blind trials in MS patients with nocturia, nasal desmopressin reduced the mean number of nocturnal voiding episodes by 31–54%.

▴ In both patient populations, desmopressin increased the initial sleep period or mean maximum period of uninterrupted sleep by ≈2 hours, an outcome significantly greater than that achieved with placebo.

▴ In trials of ≤6 weeks duration in adults with nocturia, desmopressin was generally well tolerated. Most desmopressin-related adverse events were transient and mild or moderate in severity. Clinically significant hyponatraemia was reported in ≈5% and required withdrawal from studies in š3% of patients.

Keywords

Desmopressin Secondary Efficacy Endpoint Nocturnal Polyuria Antidiuretic Effect Primary Nocturnal Enuresis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20–59 years. Acta Obstet Gynecol Scand 1997; 76: 74–80PubMedCrossRefGoogle Scholar
  2. 2.
    Jackson S. Lower urinary tract symptoms and nocturia in men and women: prevalence, aetiology and diagnosis. BJU International 1999; 84 Suppl. 1: 5–8Google Scholar
  3. 3.
    van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002; 90: 644–8PubMedCrossRefGoogle Scholar
  4. 4.
    Hale WE, Perkins LL, May FE, et al. Symptom prevalence in the elderly: an evaluation of age, sex, disease, and medication use. J Am Geriatr Soc 1986 May; 34(5): 333–40PubMedGoogle Scholar
  5. 5.
    van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 179–83PubMedCrossRefGoogle Scholar
  6. 6.
    Rembratt Å. Nocturia in the elderly: aspects on epidemiology, pathogenesis and antidiuretic treatment [doctoral thesis]. Lund: Department of Clinical and Experimental Pharmacology, Lund University, 2003Google Scholar
  7. 7.
    Barker JC, Mitteness LS. Nocturia in the elderly. Gerontologist 1988 Feb; 28(1): 99–104PubMedCrossRefGoogle Scholar
  8. 8.
    Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992 Dec; 40(12): 1217–20PubMedGoogle Scholar
  9. 9.
    Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999; 84: 297–301PubMedCrossRefGoogle Scholar
  10. 10.
    Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis: a double-blind, crossover trial. Arch Neurol 1996 Dec; 53(12): 1270–5PubMedCrossRefGoogle Scholar
  11. 11.
    Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalance of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003; 92: 948–54PubMedCrossRefGoogle Scholar
  12. 12.
    van Dijk L, Kooij DG, Schellevis FG, et al. Nocturia: impact on quality of life in a Dutch adult population. BJU Int 2004 May; 93(7): 1001–7PubMedCrossRefGoogle Scholar
  13. 13.
    Kobelt G, Borgström F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003; 91: 190–5PubMedCrossRefGoogle Scholar
  14. 14.
    Asplund R, Henriksson S, Johansson S, et al. Nocturia and depression. BJU Int 2004; 93: 1253–6PubMedCrossRefGoogle Scholar
  15. 15.
    Kallas HE, Chintanadilok J, Maruenda J, et al. Treatment of nocturia in the elderly. Drugs Aging 1999 Dec; 15(6): 429–37PubMedCrossRefGoogle Scholar
  16. 16.
    Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003 Oct; 189(4): 1106–13PubMedCrossRefGoogle Scholar
  17. 17.
    George CL, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metabol 1975; 41(2): 332–8CrossRefGoogle Scholar
  18. 18.
    Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983 Sep; 46(9): 854–5PubMedCrossRefGoogle Scholar
  19. 19.
    Vilhardt H. Basic pharmacology of desmopressin: a review. Drug Invest 1990; 2 Suppl. 5: 2–8CrossRefGoogle Scholar
  20. 20.
    Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985 Aug; 103(2): 228–39PubMedGoogle Scholar
  21. 21.
    Ferring Inc. First and only treatment approved for nocturia: under-reported condition focus of first-ever medical symposia [media release]. 2003Google Scholar
  22. 22.
    Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med 1976 Mar 4; 294(10): 507–11PubMedCrossRefGoogle Scholar
  23. 23.
    Nadvornikova H, Schuck O, Cort JH. A standardized desmopressin test of renal concentrating ability. Clin Nephrol 1980 Sep; 14(3): 142–7PubMedGoogle Scholar
  24. 24.
    Ferring AB. Desmopressin (Minirin®, DDAVP®): focus on urological indications. Chester: Adis International Ltd, 1998Google Scholar
  25. 25.
    Butlen D, Guillon G, Rajerison RM, et al. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol Pharmacol 1978; 14: 1006–17PubMedGoogle Scholar
  26. 26.
    Brink HS, Derkx FHM, Boomsma F, et al. Effects of DDAVP on renal hemodynamics and renin secretion in subjects with essential hypertension. Clin Nephrol 1994 Aug; 42(2): 95–101PubMedGoogle Scholar
  27. 27.
    Medina P, Segarra G, Vila JM, et al. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens 1999 Feb; 12 (2 Pt 1): 188–93PubMedCrossRefGoogle Scholar
  28. 28.
    Mechaly I, Laurent F, Portet K, et al. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol 1999 Nov 3; 383: 287–90PubMedCrossRefGoogle Scholar
  29. 29.
    Seif SM, Zenser TV, Ciarochi FF, et al. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus — mechanism of prolonged antidiuresis. J Clin Endocrinol Metab 1978; 46(3): 381–8PubMedCrossRefGoogle Scholar
  30. 30.
    Eller N, Kollenz CJ, Bauer P, et al. The duration of antidiuretic response of two desmopressin nasal sprays. Int J Clin Pharmacol Ther 1998 Sep; 36(9): 494–500PubMedGoogle Scholar
  31. 31.
    Vilhardt H, Bie P. Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol (Copenh) 1984; 105: 474–6Google Scholar
  32. 32.
    Fjellestad-Paulsen A, Hogland P, Lundin S, et al. Pharmaco-kinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993 Feb; 38: 177–82CrossRefGoogle Scholar
  33. 33.
    Callréus T, Lundahl J, Höglund P, et al. Changes in gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol 1999 Jun; 55(4): 305–9PubMedCrossRefGoogle Scholar
  34. 34.
    Vilhardt H, Lundin S, Falch J. Plasma kinetics of DDAVP in man. Acta Pharmacol Toxicol (Copenh) 1986; 58: 379–81CrossRefGoogle Scholar
  35. 35.
    Vilhardt H, Lundin S. Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen Pharmac 1986; 17(4): 481–3CrossRefGoogle Scholar
  36. 36.
    Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998 Feb; 48: 235–41CrossRefGoogle Scholar
  37. 37.
    Williams TDM, Dunger DB, Lyon CC, et al. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin: 1. Studies in adults and children. J Clin Endocrinol Metab 1986; 63(1): 129–32Google Scholar
  38. 38.
    Callréus T, Höglund P. Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. Pharmacol Toxicol 1998 Dec: 83(6): 259–62PubMedCrossRefGoogle Scholar
  39. 39.
    Ferring Pharmaceuticals A/S. Minirin tablets (desmopressin acetate). Data sheet: information for health professionals [online]. Available from URL: http://www.medsafe.govt.nz/Profs/Datasheet/m/Minirintab.htm [Accessed 2004 Apr 27]
  40. 40.
    D’Agay-Abensour L, Fjellestad-Paulsen A, Hoglund P, et al. Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. Eur J Clin Pharmacol 1993; 44(5): 473–6PubMedCrossRefGoogle Scholar
  41. 41.
    Robertson GL, Mahr EA, Athar S, et al. Development and clinical application of a new method for radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973 Sep; 52: 2340–52PubMedCrossRefGoogle Scholar
  42. 42.
    Beardwell CG, Geelen G, Palmer H, et al. Radioimmunoassay of plasma vasopressin in physiological and pathological states in man. J Endocrinol 1975; 67: 189–202PubMedCrossRefGoogle Scholar
  43. 43.
    Agersø H, Larsen LS, Riis A, et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 2004; 58(4): 352–8PubMedCrossRefGoogle Scholar
  44. 44.
    Edwards CRW, Kitau MJ, Chard T, et al. Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. Br Med J 1973 Aug 18; 3: 375–8PubMedCrossRefGoogle Scholar
  45. 45.
    Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002 Jun; 89(9): 855–62PubMedCrossRefGoogle Scholar
  46. 46.
    Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004 Sep; 172(3): 1021–5PubMedCrossRefGoogle Scholar
  47. 47.
    Eckford SD, Swami KS, Jackson SR, et al. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994 Dec; 74(6): 733–5PubMedCrossRefGoogle Scholar
  48. 48.
    Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996; 77: 805–12PubMedCrossRefGoogle Scholar
  49. 49.
    Donovan JL, Abrams P, Peters TJ, et al. The ICS-‘BPH’ study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 554–62PubMedCrossRefGoogle Scholar
  50. 50.
    Kirkland JL, Lye M, Levy DW, et al. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J 1983 Dec 3; 287: 1665–7CrossRefGoogle Scholar
  51. 51.
    Abrams P, Mattiasson A, Lose GR, et al. The role of desmopressin in the treatment of adult nocturia. BJU Int 2002 Dec; 90 Suppl. 3: 32–6CrossRefGoogle Scholar
  52. 52.
    Ferring Pharmaceuticals Ltd. Desmospray, desmopressin nasal spray. Summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr30]
  53. 53.
    Ferring Pharmaceuticals Ltd. DDAVP/desmopressin intranasal solution. Summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 30]
  54. 54.
    Williford SL, Bernstein SA. Intranasal desmopressin-induced hyponatremia. Pharmacotherapy 1996 Jan–Feb; 16(1): 66–74PubMedGoogle Scholar
  55. 55.
    Robson WLM. Water intoxication in patients treated with desmopressin. Pharmacotherapy Sep–Oct 1996; 16: 969–70Google Scholar
  56. 56.
    Williford SL. Water intoxication in patients treated with desmopressin: author’s reply. Pharmacotherapy Sep–Oct 1996; 16: 970Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International Limited, AucklandMairangi Bay, AucklandNew Zealand

Personalised recommendations